Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review
Introduction
Every year nearly 1 million adults in the United States are diagnosed with heart failure (HF), which is generally a result from cardiac injuries causing impairment of ventricular structure and function [1]. While we have made strides in treatment, this disease continues to have significant morbidity and mortality on par with many malignancies. Novel preventative and therapeutic HF targets are greatly needed, and gut microbiota (GMB), a community of symbiotic bacteria, fungi and viruses residing in our gastrointestinal (GI) tract, may be a source of such targets. Growing data suggests that GMB plays an important role in a myriad of important biological processes, many of which are implicated in pathogenesis and pathophysiology of cardiomyopathy (CM) and HF and its comorbidities. In this state-of-the-art review we summarize current knowledge on HF-associated GMB dysregulation and evidence supporting the role of the GMB in pathogenesis and progression of HF and its comorbidities. We close by reviewing prospects of targeting the GMB to prevent and treat HF.
Section snippets
Interplay Between the Gut and the Heart - the “Gut Hypothesis” of Heart Failure
Cardiac dysfunction induces acutely adaptive, but chronically maladaptive hemodynamic, neurohumoral and pro-inflammatory responses, which both affect the gut and are propagated by it [Fig. 1]. Gut ischemia develops in HF both due to elevated gut venous pressures and decreased blood flow in the splanchnic arteries [2]. The sequelae of chronic gut hypoperfusion and venous congestion include progressive interstitial edema and fibrosis of the gut wall, which correlate with HF severity, being most
Heart failure-associated gut dysbiosis - insights from association studies
Marked alterations in the structure and physiology of the GI tract in HF affect resident GMB communities. Methods used in the study of the GMB are reviewed extensively elsewhere [[13], [14], [15]], but in Table 1 we offer a brief primer on different approaches to study of GMB. A number of studies have examined GMB differences in HF compared to healthy individuals (Table 2 provides a summary of individual study findings) [2,3,5,[16], [17], [18], [19], [20], [21], [22]]. While heterogeneity in
Gut microbiome alterations in heart failure - more than just an association?
While these cross-sectional studies support an association between dysregulated GMB and HF pathophysiology, they do not in themselves offer a proof of the causal link between the two. Nonetheless, while the longitudinal clinical studies are still needed, in vitro, in vivo animal studies and small translational human studies have helped elucidate the active role GMB plays in the development of CM, HF, and HF-related co-morbidities.
Heart failure comorbidities and the role of the gut microbiota
Gut microbiome contributes not only to the development of cardiomyopathy and HF and to progression of HF but is also an active mediator in the pathogenesis of several conditions that develop as complications of HF, which increase the morbidity and mortality of patients with HF. Understanding how GMB is linked to HF-associated comorbidities may provide more insight into complex host-microbe relationships, which can serve as promising therapeutic targets.
Microbial-drug interactions and implications for heart failure therapeutics
While inter-individual variability in drug pharmacokinetics and pharmacodynamics caused by host genetic make-up (pharmacogenomics) has been well recognized, there is growing data to support resident GMB contributions to this phenomenon (pharmacomicrobiomics). Resident GMB and its metabolites can alter drug absorption and (in)activation. They can also compete for drug-metabolizing enzymes in the liver and alter their expression [129]. The drug-microbiome interactions are bidirectional - drugs
Targeting the Gut Microbiome to Prevent and Treat Heart Failure - Are We There Yet?
Different approaches to GMB modulation - ranging from broad and non-specific dietary interventions and fecal microbiota transplant (FMT) to ones involving specific and targeted microbial enzyme inhibition - have been proposed in many diseases. Given the role that the GMB plays in development and progression of cardiomyopathy and HF, development of its comorbidities, and modulation of the effects of HF therapy, the prospect of GMB as a preventative and therapeutic target in HF is being seriously
Conclusions
Accumulating evidence has suggested that GMB plays an important role in development and progression of HF, its comorbidities, and immune-mediated subtypes of cardiomyopathy, including myocarditis and anthracycline-induced cardiotoxicity. Microbial translocation, and altered structure and function of GMB have been consistently shown to contribute to HF, emphasizing the intense interaction between the gut and heart, known as the “gut hypothesis” of HF. Over the past decade, metabolomics has
Funding Support
Dr. Mamic is partially supported by a grant from the National Institutes of Health (F32HL143916). Dr. Tang is partially supported by grants from the National Institutes of Health (R01DK106000, R01HL126827).
Disclosure
Dr. Tang is a consultant for Sequana Medical A.G., Owkin Inc., and Relypsa Inc., and has received honorarium from Springer Nature for authorship/editorship and American Board of Internal Medicine for exam writing committee participation, all unrelated to the contents of this paper. All other authors have no relationships to disclose, both unrelated to the contents of this paper.
Fig. 1 shows that hemodynamic features of heart failure (HF), decreased cardiac output and elevated intracardiac
References (160)
- et al.
2013 ACCF/AHA guideline for the Management of Heart Failure
J. Am. Coll. Cardiol.
(2013 Oct 15) - et al.
Intestinal blood flow in patients with chronic heart failure: A link with bacterial growth, gastrointestinal symptoms, and Cachexia
J. Am. Coll. Cardiol.
(2014 Sep 16) - et al.
Altered intestinal function in patients with chronic heart failure
J. Am. Coll. Cardiol.
(2007 Oct 16) - et al.
Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure
Int. J. Cardiol.
(2008 Apr 10) - et al.
Pathogenic gut Flora in patients with chronic heart failure
JACC: Heart Failure.
(2016 Mar 1) - et al.
Endotoxin and immune activation in chronic heart failure: a prospective cohort study
Lancet
(1999 May 29) - et al.
Microbiome 101: studying, analyzing, and interpreting gut microbiome data for clinicians
Clin. Gastroenterol. Hepatol.
(2019 Jan 1) - et al.
Microbial culturomics: paradigm shift in the human gut microbiome study
Clin. Microbiol. Infect.
(2012 Dec 1) - et al.
Gut microbiota signature in heart failure defined from profiling of 2 independent cohorts
J. Am. Coll. Cardiol.
(2018 Mar 13) - et al.
Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant
J. Heart Lung Transplant.
(2020 Sep 1)
Hospitalized patients with heart failure and common bacterial infections: A Nationwide analysis of concomitant Clostridium difficile infection rates and in-hospital mortality
J. Card. Fail.
GUT MICROBIOME DIFFERS BETWEEN HEART FAILURE WITH PRESERVED EJECTION FRACTION AND AGE-MATCHED CONTROLS
Journal of the American College of Cardiology
The gut microbiome in coronary artery disease and heart failure: current knowledge and future directions
EBioMedicine.
Inhibition of histone deacetylase activity by butyrate
J. Nutr.
Gut microbial metabolite TMAO enhances platelet Hyperreactivity and thrombosis risk
Cell.
Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure
J. Card. Fail.
Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis
J. Am. Coll. Cardiol.
Trimethylamine-N-oxide and heart failure with reduced versus preserved ejection fraction
J. Am. Coll. Cardiol.
Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and toll-like receptor 4
Immunity.
Microbiota-derived indole metabolites promote human and murine intestinal homeostasis through regulation of Interleukin-10 receptor
Am. J. Pathol.
Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats
Exp. Mol. Med.
Bacterial metabolite indole modulates incretin secretion from intestinal Enteroendocrine L cells
Cell Rep.
The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair
Kidney Int.
The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells
J. Thromb. Haemost.
The effects of bile acids on β-adrenoceptors, fluidity, and the extent of lipid peroxidation in rat cardiac membranes
Biochem. Pharmacol.
Endogenous bile acids are ligands for the nuclear receptor FXR/BAR
Mol. Cell
A G protein-coupled receptor responsive to bile acids
J. Biol. Chem.
Increased secondary/primary bile acid ratio in chronic heart failure
J. Card. Fail.
Ursodeoxycholic acid in patients with chronic heart failure: A double-blind, randomized, placebo-controlled, crossover trial
J. Am. Coll. Cardiol.
Histone deacetylases as therapeutic targets — from cancer to cardiac disease
Pharmacol. Ther.
Cardiorenal syndrome
J. Am. Coll. Cardiol.
Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up
Am. Heart J.
Insulin resistance in idiopathic dilated cardiomyopathy: A possible etiologic link
J. Am. Coll. Cardiol.
Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure
Eur. J. Heart Fail.
The heart and the gut
Eur. Heart J.
Na+/H+ exchangers, NHE-1 and NHE-3, of rat intestine
Expression and localization. J Clin Invest.
Age- and tissue-specific induction of NHE3 by glucocorticoids in the rat small intestine
Am. J. Phys. Cell Phys.
Aldosterone regulation of intestinal Na absorption involves SGK-mediated changes in NHE3 and Na+ pump activity
American Journal of Physiology-Gastrointestinal and Liver Physiology.
Metabolic acidosis in rats increases intestinal NHE2 and NHE3 expression and function
American Journal of Physiology-Gastrointestinal and Liver Physiology.
Meta’omic Analytic Techniques for Studying the Intestinal Microbiome
Gastroenterology
Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure
PLoS One
Heart failure is associated with depletion of core intestinal microbiota
ESC Heart Failure.
Non-Ischemic Heart Failure With Reduced Ejection Fraction Is Associated With Altered Intestinal Microbiota
Circ J.
Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients
Sci. Rep.
Low fibre intake is associated with gut microbiota alterations in chronic heart failure
ESC Heart Failure.
Gut microbiota in cardiovascular health and disease
Circ. Res.
A metagenome-wide association study of gut microbiota in type 2 diabetes
Nature.
Alteration of gut microbiota in inflammatory bowel disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome
Pathogens.
The relationship between gut microbiota and inflammatory diseases: the role of macrophages
Front. Microbiol.
Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites
PNAS.
Cited by (51)
Gut Microbiome in Cardiovascular Disease and Heart Failure: Seeing the Iceberg Below Its Surface
2023, JACC: Heart FailureGut microbiota dysbiosis and cardiovascular disease – The chicken and the egg
2023, Revista Portuguesa de CardiologiaThe Role of Gut Microbiota and the Potential Effects of Probiotics in Heart Failure
2024, Medicina (Lithuania)